Physician profile
Mina Han
NPI 1548798473
$3,140.28
in general payments reported to CMS, 2019-2025
12 companies · $2,094 in 2025
The $2,094 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.41 · 2021: $15.85 · 2023: $95.73 · 2024: $917 · 2025: $2,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395 · Travel and Lodging: $687 · Entertainment: $25.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.22 |
| Travel and Lodging | $686.60 |
| Entertainment | $25.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,458.60 | 2020-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $1,030.43 | 2023-2025 | Dailies Total1, Precision 1, Precision7 |
| Glaukos Corporation | $181.33 | 2024 | Photrexa |
| Bausch & Lomb Americas INC. | $115.86 | 2025 | Miebo |
| Johnson & Johnson Vision Care, INC. | $100.08 | 2023-2025 | Acuvue |
| Astellas Pharma US INC | $79.64 | 2024 | Izervay |
| Lkc Technologies, INC. | $76.96 | 2025 | |
| Optos, INC. | $25.20 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sight Sciences, INC. | $20.76 | 2025 | Tearcare System |
| Biotissue Holdings INC. | $18.60 | 2025 | |
| Amgen INC. | $16.70 | 2025 | Tepezza |
| Abbvie INC. | $16.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.